Abstract #2759

Metabolic dynamics of hyperpolarized [1-13C] pyruvate in human prostate cancer

Kristin L Granlund^1,2, Hebert A Vargas¹, Serge K Lyashchenko³, Phillip J DeNoble³, Vincent A Laudone⁴, James Eastham⁴, Ramon A Sosa¹, Matthew A Kennedy¹, Duane Nicholson¹, YanWei W Guo¹, Albert P Chen⁵, James Tropp⁶, Hedvig Hricak^1,2, and Kayvan R Keshari^1,2

¹Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ²Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ³Radiochemistry & Imaging Probes (RMIP) Core, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ⁴Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ⁵GE Healthcare, Toronto, ON, Canada, ⁶GE Healthcare, Fremont, CA, United States

Hyperpolarized (HP) pyruvate has the potential to improve tumor grading and evaluate response to treatment by probing the metabolism of lesions. Three patients with biopsy-proven prostate cancers have been scanned with a 2D dynamic hyperpolarized pyruvate protocol. Repeatability has been evaluated in 2 patients to date. The data from these first 5 injections confirm that HP prostate imaging is feasible and reproducible, and the 2D dynamics will inform 3D static acquisition timing.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.